BlueYard x Nucleate Partnership
We are entering a new frontier in biology and medicine unparalleled in human history, with breakthrough advances in gene editing, computational methods, and cell therapies. At the same time, our overall capability of understanding and manipulating biology is improving exponentially. BlueYard’s strategy around biology is based on the premise that humankind’s ability to engineer biology will not only fundamentally transform how we diagnose, treat, and manage diseases, but also will reinvent how we produce new materials and the food required to support human life and sustain our planet. In short: from cost digression to programmability: biology has and is undergoing several step-function changes. In recognition of these step-function changes, over the last years, we have backed a dozen companies in the space — ranging from cellular reprogramming to sustainable materials.
We believe tomorrow’s industry-defining biology companies will be founded by technologists and scientists who are building the interconnected elements that can become the fabric of our future (see our v2 thesis). We are excited about empowering this next generation of founders. Last year we launched our first fellowship in biology and science where we work side by side with a few exceptional individuals. As part of our goal to foster more innovation at the frontiers of science and technology at the earliest stages, today we are announcing our newest collaboration by partnering with Nucleate, a student-led non-profit organization dedicated to empowering the next generation of biotech leaders, with chapters spanning 23 geographic regions and participation from over 120 academic institutions, providing early funding for teams in the Nucleate program (read more here). Via our partnership with Nucleate we plan to commit a pool of $2 million in SAFE agreements to fund the next generation of founders that have made it through the organization’s six-month Activator Program during 2023. The objective is to back 10 to 20 new teams across the European ecosystem as they migrate from the academic lab to a commercial entity and build the new platforms that re-engineer our society’s biology experiences.